Brief: Respiratorius gets Orphan Drug Designation for VAL001 in EU

Respiratorius AB (publ)

21/11/2016 15:20

Nov 21 (Reuters) - Respiratorius AB  RESPS.ST : 
    * Says has received Orphan Drug Designation for its drug candidate VAL001 
for treatment of diffuse large b-cell lymphoma following decision by European 
Commission  
    * Will obtain market exclusivity for ten years in EU, from date of marketing 
approval, and free consultation and scientific advice on contact with the 
European Medicinal Agency 
 
     
 Source text: http://bit.ly/2genL5l 
     
 Further company coverage:  RESPS.ST   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))